Detail page

Knowledge Web

Person

Peter Schirmacher (1961-)

Arzt

Name	Peter Schirmacher
Time	1961- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession)
Variant	P. Schirmacher
Related	Klinikum Heidelberg Deutsche Akademie der Naturforscher Leopoldina (Mitglied, Matrikelnummer 07508) (2012-) Universität Heidelberg Pathologie, Molekularpathologie (Thema)
Further information	Ärztlicher Direktor des Pathologischen Instituts, Universitätsklinikum Heidelberg
Source	https://www.klinikum.uni-heidelberg.de/personen/prof-dr-med-peter-schirmacher-3128 (Stand: 03.08.2021)
Record type	Person
GND-Identifier	1020440112
Record ID	1020440112
Involved in show all Sarcoma classification by DNA methylation profiling Tumour mutational burden: clinical utility, challenges and emerging improvements KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication Molecular diagnostics of hepatobiliary and pancreatic neoplasias Correction: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer Standardisierte und qualitätsgesicherte prädiktive PD-L1-Testung im oberen Gastrointestinaltrakt Benchmarking whole exome sequencing in the German network for personalized medicine Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion S3-Leitlinie Diagnostik und Therapie biliärer Karzinome : Kurzversion Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis Qualitätssicherung in der Pathologie Precision oncology for intrahepatic cholangiocarcinoma in clinical practice Erratum zu: Gene und Pathways: FGFR2-Translokationen und Fusionsanalytik Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing Gene und Pathways: FGFR2‑Translokationen und Fusionsanalytik Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) Struktur und Inhalt der EU-IVDR : Bestandsaufnahme und Implikationen für die Pathologie Qualitätssicherung im Gewebebiobanking – Ein Überblick Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies? S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome : Langversion 2.0 – Juni 2021 – AWMF-Registernummer: 032-053OL S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome : Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL Biobanking in times of crisis – The COVID-19 Autopsy and Biosample Registry Baden-Wuerttemberg Framework and baseline examination of the German National Cohort (NAKO) Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure : a nationwide register study report Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies? Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies? Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen = Diagnosis and therapy of tumors with NTRK gene fusion Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer Circulating Folate and Folic Acid Concentrations: Associations With Colorectal Cancer Recurrence and Survival Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen Expanding pancreas donor pool by evaluation of unallocated organs after brain death : : study protocol clinical trial (SPIRIT Compliant) Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics The BRCA2 mutation status shapes the immune phenotype of prostate cancer Association between serum IgG level and clinical course in primary sclerosing cholangitis Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays Nucleoporin Nup155 is part of the p53 network in liver cancer

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Peter Schirmacher (1961-)

Sarcoma classification by DNA methylation profiling

Tumour mutational burden: clinical utility, challenges and emerging improvements

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma

Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication

Molecular diagnostics of hepatobiliary and pancreatic neoplasias

Correction: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

Standardisierte und qualitätsgesicherte prädiktive PD-L1-Testung im oberen Gastrointestinaltrakt

Benchmarking whole exome sequencing in the German network for personalized medicine

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort

Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis

Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal tract

Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients

α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration

Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome : Kurzversion

Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis

Qualitätssicherung in der Pathologie

Precision oncology for intrahepatic cholangiocarcinoma in clinical practice

Erratum zu: Gene und Pathways: FGFR2-Translokationen und Fusionsanalytik

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

Gene und Pathways: FGFR2‑Translokationen und Fusionsanalytik

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)

Struktur und Inhalt der EU-IVDR : Bestandsaufnahme und Implikationen für die Pathologie

Qualitätssicherung im Gewebebiobanking – Ein Überblick

Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?

S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome : Langversion 2.0 – Juni 2021 – AWMF-Registernummer: 032-053OL

S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome : Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL

Biobanking in times of crisis – The COVID-19 Autopsy and Biosample Registry Baden-Wuerttemberg

Framework and baseline examination of the German National Cohort (NAKO)

Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure : a nationwide register study report

Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?

Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?

Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement

Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report

Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin

Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen = Diagnosis and therapy of tumors with NTRK gene fusion

Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen

Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria

Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

Circulating Folate and Folic Acid Concentrations: Associations With Colorectal Cancer Recurrence and Survival

Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen

Expanding pancreas donor pool by evaluation of unallocated organs after brain death : : study protocol clinical trial (SPIRIT Compliant)

Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy

NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis

Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium

HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer

DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

Association between serum IgG level and clinical course in primary sclerosing cholangitis

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays

Nucleoporin Nup155 is part of the p53 network in liver cancer